Über uns

Immatics Biotechnologies is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer.

Our transformative product candidates are - best in class - Adoptive Cell Therapies and Bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics'​ proprietary and world-leading XPRESIDENT® technology.

Our mission is to bring the power of T-cell redirecting immunotherapies to cancer patients.

Quick Facts

· 150 Team members

· >100 Targets covering 20 major solid and liquid tumors

· About 80% of discovered targets are novel

· 2 proprietary technology platforms

· 8 proprietary development programs, thereof 2 in the clinic in 2017

· Multiple partnered programs

· Raised more than $230m in cash in five financings

Find us on Twitter and LinkedIn as well.

Legal Notice: https://immatics.com/legal-notice.html